title: A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.
abstract: A phase II clinical trial for head and neck squamous cell cancer (HNSCC) patients using multiple peptides vaccine derived from tumor-associated antigens (TAAs) was performed. The therapy was well tolerated and overall survival was statistically significantly longer in vaccinated patients, and the patients exhibiting cytotoxic T lymphocytes (CTL) responses to multiple peptides exhibited better prognosis.
authors.affiliation: Department of Oral and Maxillofacial Surgery; Graduate School of Medical Sciences; Kumamoto University ; Kumamoto, Japan ; Itoh Dent-Maxillofacial Hospital ; Kumamoto, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yoshitake
authors.affiliation: Department of Immunogenetics; Graduate School of Medical Sciences; Kumamoto University ; Kumamoto, Japan.
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Nishimura
authors.affiliation: Laboratory of Molecular Medicine; Human Genome Center; Institute of Medical Science; University of Tokyo ; Tokyo, Japan ; Department of Medicine; University of Chicago ; Chicago, IL USA.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Department of Oral and Maxillofacial Surgery; Graduate School of Medical Sciences; Kumamoto University ; Kumamoto, Japan ; Itoh Dent-Maxillofacial Hospital ; Kumamoto, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Shinohara
keywords: cancer vaccine therapy; cytotoxic T lymphocytes; head and neck squamous cell cancer; multiple peptides vaccine; phase II clinical trial; tumor-associated antigens